Source:http://linkedlifedata.com/resource/pubmed/id/14581347
Clin. Cancer Res. 2003 Oct 15 9 13 4761-71
General Info
Abstract
To assess the feasibility of administering tipifarnib, an oral nonpeptidomimetic competitive inhibitor of farnesyltransferase, in combination with gemcitabine and recommend doses for disease-directed clinical trials. The study also sought to identify drug-drug pharmacokinetic interactions, evaluate effects on protein farnesylation, and seek preliminary evidence for clinical activity.
PMID
14581347
Publication types
Clinical Trial; Research Support, U.S. Gov't, P.H.S.; Clinical Trial, Phase I